Priority review is the SFDA's mechanism for expediting the assessment of medicines that treat serious or life-threatening conditions, address an unmet medical need, or are the first biosimilar to an innovator product. The current guidance is Version 5.3, dated 11 February 2024 (document 140225/V5.3-003-G-DS); the first version was issued in October 2013 and implemented in February 2014. It is one of the routes described in the SFDA Regulatory Framework for Drug Approval.
What priority review changes — and what it does not
Priority review means the concerned SFDA departments expedite the review process. It is worth being precise about the limit of that: the guidance states that designating a product as priority review does not alter any of the scientific standards or the quality of evidence required for approval.
In other words, priority review buys time, not leniency. A dossier that would fail on the standard route will fail on this one. The guidance also extends to veterinary drugs meeting the stated criteria.
Route A — new drugs and biologics
For a new chemical entity introduced by the innovator (or its partner) and for biological drugs, priority review is intended for products treating a serious or life-threatening condition and/or demonstrating potential to address unmet medical need. The guidance treats serious and life-threatening conditions as one category for eligibility purposes.
For a condition to be serious, it must be associated with morbidity that has a substantial impact on day-to-day functioning. Short-lived, self-limiting morbidity will usually not suffice — though the morbidity need not be irreversible, provided it is persistent or recurrent.
The product must also be intended to treat a serious aspect of the condition, not merely be used in patients who have it. A product evaluated for its effect on serious manifestations or symptoms qualifies; so does one evaluated for improving diagnosis or detection, where the data give a strong basis for presuming better outcomes follow.
What counts as addressing an unmet medical need
An unmet medical need is one not adequately addressed by existing therapy. Where no therapy exists for a serious condition, the unmet need is obvious. Where therapies do exist, the development programme must evaluate at least one of the following:
- Improved effect on serious outcomes already affected by alternative therapies.
- Effect on serious outcomes not known to be affected by the alternatives.
- Benefit in patients unable to tolerate or unresponsive to alternatives, or usable in combination with critical agents that cannot be combined with available therapy.
- Benefit similar to alternatives while avoiding serious toxicity present in existing therapies, or avoiding common less-serious toxicity that causes patients to discontinue treatment of a serious disease.
- Benefit similar to alternatives but with an improvement — in compliance or convenience, for example — shown to lead to improved effects on serious outcomes.
Route B — biosimilars, and Route C — availability
For biosimilars, priority review is intended for the product considered the first biosimilar to an innovator product already registered with the SFDA or with a stringent regulatory authority. Being first is the qualifying condition, not merely being a biosimilar.
A third route addresses availability. A priority review request for an unavailable drug is assessed against whether the product appears on one of the SFDA's updated lists for unregistered or unavailable products, whether registered alternatives fail to cover local market needs, and whether the product appears on a national mandatory list.
What changed in version 5.3 — and why it matters
Version 5.3 deleted the criteria for first generic from the qualifying conditions and updated the application form. Version 5.2 had earlier updated the biosimilar criteria.
This is the practical trap. A company working from a pre-5.3 copy of the guidance, or from a consultant's summary written against an older version, may still believe a first generic can qualify for priority review. It cannot. Always plan against the current version — and check the document control table on page four before relying on any copy.
How MRG supports a priority review application
MRG holds SFDA Consultation Office license CO-2023-FO-0022 and assesses eligibility against the current version of the guidance before any work is committed — including the honest answer where a product does not qualify. We prepare the designation argument, the supporting summaries of available data, and manage submission through the SDR system alongside the registration dossier itself. For the underlying filing process, see our guide to SFDA drug registration in Saudi Arabia.
If you are unsure whether your product qualifies, or which of the three routes applies, talk to our consultants or explore our pharmaceutical regulatory services in Saudi Arabia.
Key Takeaway
SFDA priority review expedites assessment for new drugs and biologics treating serious conditions or addressing unmet need, for the first biosimilar to a registered innovator product, and for products on the SFDA's unavailable or national mandatory lists. It does not lower the evidential bar. Version 5.3 removed first generics from the qualifying criteria, so eligibility should always be checked against the current document rather than an older summary.
Frequently Asked Questions
What qualifies a product for SFDA priority review?
Three routes. New drugs and biologics treating a serious or life-threatening condition and/or addressing unmet medical need; the first biosimilar to an innovator product already registered with the SFDA or a stringent regulatory authority; and unavailable products meeting the SFDA's availability criteria.
Does SFDA priority review lower the evidence requirements?
No. The guidance is explicit that designating a product as priority review does not alter any of the scientific standards or the quality of evidence required for approval. It expedites the review process only.
Can a first generic get SFDA priority review?
Not under the current guidance. Version 5.3, dated 11 February 2024, deleted the criteria for first generic. Companies working from an earlier version of the guidance may still assume it qualifies.
What counts as a serious condition for SFDA priority review?
A condition associated with morbidity that has a substantial impact on day-to-day functioning. Short-lived and self-limiting morbidity is usually insufficient, though morbidity need not be irreversible provided it is persistent or recurrent. The product must also treat a serious aspect of the condition.
